Celgene beats estimates in earnings and sales

25 January 2018
2019_biotech_test_vial_discovery_big

Fresh from announcing a huge $9 billion  takeover of CAR-T cell therapy specialist Juno Therapeutics, Celgene (Nasdaq: CELG) has announced better-than-predicted results for the last quarter of 2017.

The US biotech group reported adjusted earnings-per-share of $2 and revenues of $3.48 billion, beating Wall Street estimates of $1.97 and $3.46 billion respectively.

Both the quarterly revenue figure and the total for 2017 as a whole – of $13 billion – represent rises of around 16% to 17% compared to the previous year, with Revlimid (lenalidomide), which provides 60% of Celgene’s sales, responsible for much of the growth.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology